As of yet, epidermal growth factor receptor (EGFR) inhibition has not shown clinical efficacy in pancreatic cancer,15 but no study has investigated the efficacy of EGFR inhibitors in periampullary adenocarcinoma in relation to morphology. This evidence concerns the gene EGFR and periampullary adenocarcinoma.